Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	11/1/2018 1:03:21 AM
	Read Replies (1) of 3559

Few tid-bits from Sanofi 3Q cc: -Dupi US sale was $220m, ex-US $42m, total $262m,...bit better than projected. -Kevzara/Praluent.... in line with expected -focus on Dupi-asthma lunch, while REGN2810 (anti-PD1) is out of focus...not even me-too drug???? I guess, none expect that they can compete against Opdivo/Keytruda. -profitability from collaboration, not until 2020.....which is very puzzling to me? How to calculate/project marketing expense???? That is Sanofi position,... REGN should be profitable from collaboration in 2019. In all, ...it is up to Eylea and CMS!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next